RxDoctor Payments Data

Jennifer Bowring

Physician Assistant · Dallas, TXNPI 1265080287

Payments from drug & device makers

$2,368in general payments, 2019–2025

Across 124 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$510
  • Novo Nordisk$326
  • Amgen$250
  • Abbott$235
  • AbbVie$205
  • GSK$182
  • plus $659 from 21 others

What the payments were for

  • Food & beverage$2,368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,368 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$25,532
Medicare patients
128
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate12$19,262
EliquisApixaban17$13,756
Atorvastatin Calcium85$1,053
Levothyroxine Sodium57$696
Gabapentin28$559
Wixela InhubFluticasone Propion/Salmeterol11$508
Pravastatin Sodium36$489
Metoprolol Succinate44$453
Losartan Potassium43$442
Zolpidem Tartrate ErZolpidem Tartrate17$388
Azelastine Hcl12$347
Omeprazole19$299
Lisinopril34$277
Pregabalin14$253
Trazodone Hcl30$232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$41$19,26212 claims
PfizerEliquis$75$13,75617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →